Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD
Overview
Authors
Affiliations
Objective: To develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment.
Methods: To illustrate its research-enabling purpose, epidemiologic patterns and disease phenotypes were assessed among enrolled subjects, including age at disease onset, annualized relapse rate (ARR), and time between the first and second attacks.
Results: As of December 2017, the Collaborative International Research in Clinical and Longitudinal Experience Study (CIRCLES) had enrolled more than 1,000 participants, of whom 77.5% of the NMOSD cases and 71.7% of the controls continue in active follow-up. Consanguineous relatives of patients with NMOSD represented 43.6% of the control cohort. Of the 599 active cases with complete data, 84% were female, and 76% were anti-AQP4 seropositive. The majority were white/Caucasian (52.6%), whereas blacks/African Americans accounted for 23.5%, Hispanics/Latinos 12.4%, and Asians accounted for 9.0%. The median age at disease onset was 38.4 years, with a median ARR of 0.5. Seropositive cases were older at disease onset, more likely to be black/African American or Hispanic/Latino, and more likely to be female.
Conclusions: Collectively, the CIRCLES experience to date demonstrates this study to be a useful and readily accessible resource to facilitate accelerating solutions for patients with NMOSD.
Gholizadeh S, Exuzides A, Sinnott J, Palmer C, Waltz M, Rose J Sci Rep. 2024; 14(1):26150.
PMID: 39477975 PMC: 11525583. DOI: 10.1038/s41598-024-75013-z.
Vlahovic L, McDonald J, Hinman J, Tomczak A, Lock C, Palmer C Neurology. 2024; 102(1):e207965.
PMID: 38165361 PMC: 10834131. DOI: 10.1212/WNL.0000000000207965.
Chu F, Shi M, Liu C, Zhu J Clin Exp Immunol. 2023; 213(3):363-370.
PMID: 37161978 PMC: 10570998. DOI: 10.1093/cei/uxad053.
Ladakis D, Bhargava P CNS Drugs. 2023; 37(2):117-132.
PMID: 36690786 DOI: 10.1007/s40263-023-00986-w.
Gholizadeh S, Exuzides A, Lewis K, Palmer C, Waltz M, Rose J J Neurol. 2022; 270(4):2048-2058.
PMID: 36565348 PMC: 10025181. DOI: 10.1007/s00415-022-11529-6.